IPP Bureau
Oppilotech and Evariste technologies partner for anti-bacterial programme
By IPP Bureau - March 16, 2022
Machine learning approach to systems biology combined with ligand discovery platform
UFDA approves first generic of Symbicort to treat asthma and COPD
By IPP Bureau - March 16, 2022
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
Onco aims to make cancer care affordable
By IPP Bureau - March 16, 2022
Onco Care Plus is available at just INR 399 per month, and provides services like free doctor consultation, 15% off on cancer treatment costs, 25% off for diagnostic tests, free nutrition plans, among many more
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
By IPP Bureau - March 16, 2022
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Bharat Biotech and Biofabri to develop and distribute novel TB vaccine
By IPP Bureau - March 16, 2022
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
SRL Diagnostics and Roche Diagnostics partner to establish an integrated lab
By IPP Bureau - March 16, 2022
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
Boston Scientific opens second R&D centre in Pune
By IPP Bureau - March 16, 2022
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
BSV invests in solar power project as part of it sustainability commitment
By IPP Bureau - March 16, 2022
This investment will help BSV avoid carbon dioxide emissions by as much as 6560 tonnes of carbon dioxide equivalent (tCO2e) annually over its project life of 25 years
I Peace triples GMP cell manufacturing by expanding CDMO facility
By IPP Bureau - March 15, 2022
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
NuclixBio and PharmAbcine sign collaborative research agreement
By IPP Bureau - March 15, 2022
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
USFDA grants Orphan Drug Designation for Akantior
By IPP Bureau - March 15, 2022
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Single-cell DNA sequencing identifies genetic mechanism in brain lesion formation
By IPP Bureau - March 15, 2022
Tapestri Platform powers Nature Cardiovascular Research publication that identifies two somatic mutations associated with sporadic brain blood vessel disorder
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
By IPP Bureau - March 15, 2022
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Srichakra receives European Food Safety approval for its food-grade recycled rPET
By IPP Bureau - March 15, 2022
Srichakra receives European Food Safety approval for its food-grade recycled rPET
Uniphore and SpinSci join hands to improve patient access and engagement
By IPP Bureau - March 15, 2022
Deploying solutions like Uniphore’s U-Self Serve and U-Assist with SpinSci’s Patient Engage and Patient Assist is an important step forward in creating frictionless patient experiences
